LEXINGTON, Mass.--(BUSINESS WIRE)--EPIX Pharmaceuticals, Inc. (OTCBB: EPIX.OB), a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly efficient in silico drug discovery platform, announced today that the holders of its $3.2 million outstanding balance of 3% Convertible Senior Notes Due 2024 will have the right to require EPIX to repurchase the Notes on August 5, 2009.
